Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

/p>

The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials.

Cinryze is for intravenous use only. Per the U.S. label, a dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States and approximately similar demographics in the European Union.

For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org or the HAEi (International Patient Organization for C1 Inhibitor Deficiencies) at www.haei.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... YORK, Pa. , July 1, 2015  Unilife ... developer, manufacturer and supplier of injectable drug delivery systems, ... been amended as of June 30, 2015. This amendment ... least $20 million in cash receipts from customers during ... no other adjustments to any of the terms of ...
(Date:7/1/2015)... Qiming Venture Partners, today announces the promotion ... immediately. William has been with Qiming for ... many Qiming healthcare deals, and assisted many of these ... s success in healthcare is not a small part ... his outstanding advocacy and service mentality on behalf of ...
(Date:7/1/2015)... -- According to a new market research ... (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral), by ... to 2020", published by MarketsandMarkets, the Transfection Reagents and ... by 2020 with a CAGR of 7.2% from 2014 ... ables and 33 F igures ...
Breaking Medicine Technology:Unilife and OrbiMed Amend Debt Financing Agreement 2Unilife and OrbiMed Amend Debt Financing Agreement 3Qiming Announces the Promotion of William Hu to Managing Partner 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4
... Oct. 5 Alma Lasers, a global developer, ... ultrasound devices for aesthetic and medical applications announced ... supporters committed to fighting breast cancer through awareness, ... Awareness and the newly launched SopranoXLi Pain-Free Hair-Free ...
... Oct. 5 According to Millennium Research Group (MRG), ... Canadian interventional cardiology device market is a highly competitive ... competitors fighting for market share in this extremely profitable ... a $55 million market -- the most lucrative of ...
Cached Medicine Technology:Alma Lasers Joins the Fight Against Breast Cancer with the Launch of the NEW SopranoXLi 2Canadian Health Care System Pressuring Manufacturers to Lower Drug-Eluting Stent Prices in US$55 Million Market 2Canadian Health Care System Pressuring Manufacturers to Lower Drug-Eluting Stent Prices in US$55 Million Market 3
(Date:7/2/2015)... ... 2015 , ... Denver-based SlimGenics Weight Control Centers, the leader ... 14 on ColoradoBiz magazine’s Top 100 Woman-Owned Companies list. ColoradoBiz compiles the exclusive ... award identifies outstanding woman-owned businesses that demonstrate excellence and success in the industry ...
(Date:7/1/2015)... ... 2015 , ... With all final regulatory approvals in place ... N.Y., is now a member of national system Trinity Health, effective immediately. ... committed to delivering high-value care, said Richard J. Gilfillan, M.D., president and CEO, ...
(Date:7/1/2015)... ... 01, 2015 , ... For decades, researchers in the genetics field have theorized ... brain, never changing after development in the womb. Now, researchers from the Icahn School ... cells throughout life – a process which helps to switch genes on and off. ...
(Date:7/1/2015)... ... 01, 2015 , ... Ormco Corporation, a leading manufacturer and ... Smile for a Lifetime Foundation (S4L) fundraising event held at the 14th Annual ... S4L in its mission to provide free quality orthodontic care to individuals with ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Collaborative for Children and ... Community Trust. The grant will allow CCF to improve quality of care and save ... was formed to respond to many changes in New York’s Medicaid system. Experts agree ...
Breaking Medicine News(10 mins):Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that ... (GBM) has a favorable safety profile and extends survival ... median survival rate. Patients in the study, conducted ... San Francisco and Columbia University, were found to have ...
... the most vulnerable group are the elderly. Writing in ... in New Zealand suggest that emergency response plans must ... regards to the personal and social resources they have ... University in Palmerston North, point out that elderly citizens ...
... is one of the leading causes of death. Chronic, localized ... fibrous plaques, which leads to narrowing or occlusion of the ... of the inflammatory reaction is due to a loss of ... cells are known to play a central role in the ...
... 2011Hospitals that provide quality care for young people do not ... new study has found. As our population ages and ... care they provide for the over 65s and implement programs ... Avery Nathens, trauma director at St. Michael,s Hospital. The ...
... HealthDay Reporter , THURSDAY, June 2 (HealthDay News) -- ... coli bacteria in Europe should serve as a red ... constantly mutating and changing. They,re not necessarily becoming more severe, ... an attending physician in infectious diseases at North Shore University ...
... (HealthDay News) -- They are meant to protect football players, ... faceshields are more likely to break on high-velocity impact. ... State University, also found that only about 50 percent of ... used or damaged shields. In the study, published in ...
Cached Medicine News:Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 2Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 3Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 4Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 5Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 6Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 7Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 8Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 9Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 10Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 11Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 12Health News:Helping the aged during natural disasters 2Health News:Fast track to vascular disease 2Health News:Fast track to vascular disease 3Health News:Not all hospitals treat elderly the same 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 3Health News:Used Football Faceshields May Break on Impact 2
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
The Trident PSL Acetabular Shells are designed to maximize fixation in the peripheral lunate region of the acetabulum....
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Medicine Products: